"Peptides, Cyclic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Peptides whose amino and carboxy ends are linked together with a peptide bond forming a circular chain. Some of them are ANTI-INFECTIVE AGENTS. Some of them are biosynthesized non-ribosomally (PEPTIDE BIOSYNTHESIS, NON-RIBOSOMAL).
| Descriptor ID |
D010456
|
| MeSH Number(s) |
D04.345.566 D12.644.641
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Peptides, Cyclic".
Below are MeSH descriptors whose meaning is more specific than "Peptides, Cyclic".
This graph shows the total number of publications written about "Peptides, Cyclic" by people in this website by year, and whether "Peptides, Cyclic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 1 | 0 | 1 |
| 2003 | 1 | 0 | 1 |
| 2004 | 2 | 0 | 2 |
| 2007 | 0 | 1 | 1 |
| 2009 | 1 | 1 | 2 |
| 2010 | 0 | 1 | 1 |
| 2011 | 1 | 0 | 1 |
| 2019 | 0 | 1 | 1 |
| 2020 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Peptides, Cyclic" by people in Profiles.
-
An evaluation of the Acromegaly Treatment Satisfaction Questionnaire (Acro-TSQ) in adult patients with acromegaly, including correlations with other patient-reported outcome measures: data from two large multicenter international studies. Pituitary. 2020 Aug; 23(4):347-358.
-
Development of a novel patient-reported measure for acromegaly: the Acro-TSQ. Pituitary. 2019 Dec; 22(6):581-593.
-
An angiogenic inhibitor, cyclic RGDfV, attenuates MPTP-induced dopamine neuron toxicity. Exp Neurol. 2011 Sep; 231(1):160-70.
-
Comment on: Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis. Rheumatology (Oxford). 2010 Sep; 49(9):1795-6; author reply 1796-7.
-
Laboratory tests to assess patients with rheumatoid arthritis: advantages and limitations. Rheum Dis Clin North Am. 2009 Nov; 35(4):731-4, vi-vii.
-
Quantitative clinical rheumatology: why is a test for anti-CCP antibodies included in most routine care for rheumatoid arthritis while a HAQ/MDHAQ remains largely a research tool? J Rheumatol. 2009 Aug; 36(8):1563-4.
-
N-of-1 trial of low-dose methotrexate and/or prednisolone in lieu of anti-CCP, MRI, or ultrasound, as first option in suspected rheumatoid arthritis? J Rheumatol. 2007 Feb; 34(2):250-2.
-
Safety and efficacy of micafungin in transplantation recipients. Transplantation. 2006 Dec 15; 82(11):1549.
-
Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder. J Natl Cancer Inst. 2004 Oct 06; 96(19):1447-57.
-
Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J Clin Microbiol. 2004 Aug; 42(8):3475-82.